AIRLINK 74.29 Increased By ▲ 0.29 (0.39%)
BOP 4.95 Decreased By ▼ -0.07 (-1.39%)
CNERGY 4.37 Decreased By ▼ -0.05 (-1.13%)
DFML 38.80 Decreased By ▼ -0.40 (-1.02%)
DGKC 84.82 Decreased By ▼ -1.27 (-1.48%)
FCCL 21.21 Decreased By ▼ -0.44 (-2.03%)
FFBL 34.12 Increased By ▲ 0.11 (0.32%)
FFL 9.70 Decreased By ▼ -0.22 (-2.22%)
GGL 10.42 Decreased By ▼ -0.14 (-1.33%)
HBL 113.00 Decreased By ▼ -0.89 (-0.78%)
HUBC 136.20 Increased By ▲ 0.36 (0.27%)
HUMNL 11.90 No Change ▼ 0.00 (0%)
KEL 4.71 Decreased By ▼ -0.13 (-2.69%)
KOSM 4.44 Decreased By ▼ -0.09 (-1.99%)
MLCF 37.65 Decreased By ▼ -0.62 (-1.62%)
OGDC 136.20 Increased By ▲ 1.35 (1%)
PAEL 25.10 Decreased By ▼ -1.25 (-4.74%)
PIAA 19.24 Decreased By ▼ -1.56 (-7.5%)
PIBTL 6.71 Increased By ▲ 0.03 (0.45%)
PPL 122.10 Decreased By ▼ -0.90 (-0.73%)
PRL 26.65 Decreased By ▼ -0.04 (-0.15%)
PTC 13.93 Decreased By ▼ -0.40 (-2.79%)
SEARL 57.22 Decreased By ▼ -1.90 (-3.21%)
SNGP 67.60 Decreased By ▼ -1.90 (-2.73%)
SSGC 10.25 Decreased By ▼ -0.08 (-0.77%)
TELE 8.40 Decreased By ▼ -0.10 (-1.18%)
TPLP 11.13 Decreased By ▼ -0.10 (-0.89%)
TRG 62.81 Decreased By ▼ -2.04 (-3.15%)
UNITY 26.50 Increased By ▲ 0.25 (0.95%)
WTL 1.35 Increased By ▲ 0.01 (0.75%)
BR100 7,810 Decreased By -40.3 (-0.51%)
BR30 25,150 Decreased By -186.4 (-0.74%)
KSE100 74,957 Decreased By -250.1 (-0.33%)
KSE30 24,083 Decreased By -59.5 (-0.25%)

European scientists close to coronavirus antibody treatment breakthrough

  • Antibody injections instantly arm the body with the ability to neutralize the virus and the treatment could be a game-changer for those in early stages of infection
Published June 8, 2020

(Karachi) Scientists from the UK and Sweden, who have been efforting to develop coronavirus vaccine, are reportedly close to a breakthrough on an antibody treatment for COVID-19 that could prove a lifesaver for those who become infected by the virus.

The British-Swedish drug-manufacturing giant AstraZeneca is developing the treatment, which may initially be used to treat elderly and vulnerable patients.

Antibody injections instantly arm the body with the ability to neutralize the virus, and the treatment could be a game-changer for those in the early stages of infection.

AstraZaneca’s Head Pascal Soriot said, "The treatment being developed is a combination of two antibodies, because by having both you reduce the chance of resistance developing to one antibody."

Antibody therapy is more expensive than vaccine production, however, with Soriot saying the former would be prioritized for the elderly and vulnerable, “who may not be able to develop a good response to a vaccine.”

The treatment is now being tested at “full speed,” and executives are hopeful that it will go into full production next year.

Earlier, speaking during a programme, Pascal Soriot said the firm is starting production of a potential coronavirus vaccine in a bid to meet demand if the drug proves effective.

He added, “We are starting to manufacture this vaccine right now.”He said the firm would know by August whether the vaccine works or not.

He mentioned that trials of the drug are under way and it needs to to be ready for use by the time the company gets results.

Comments

Comments are closed.